Ovid Therapeutics appoints Zhong as CSO, Malhotra as CMO

Ovid Therapeutics (OVID) announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic development programs. The Company also announced changes to its administrative functions intended to enhance efficiency and reduce costs. Scientific Leadership & Development Appointments: Dr. Zhong Zhong joins Ovid as Chief Scientific Officer, CSO, and Dr. Manoj Malhotra assumes role as Chief Medical Officer, CMO, following the planned retirement of Dr. Claude Nicaise. Prior to joining Ovid, Dr. Zhong served in senior leadership and scientific roles at Generation Bio (GBIO). Dr. Zhong will partner closely with Dr. Manoj Malhotra who is taking on an expanded role as Chief Medical Officer. Corporate Strategy & Leadership Appointment: In addition to deepening its bench of scientific leadership, Ovid expanded the role of Meg Alexander to the position of Chief Strategy Officer. In this remit, she will oversee Ovid’s corporate strategy and planning, performance measurement, and risk mitigation. General & Administrative Infrastructure Cost Reductions & Operational Efficiencies: The Company continues to expect that its capital should fund operations into the first half of 2025. Additionally, Ovid is eligible for significant milestones and royalties if soticlestat is approved and commercialized, which would serve as a long-term and non-dilutive capital source for the Company.